Molecular Partners AG
MOLN
Classifica tra le azioni
#19481
Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to... Molecular Partners AG is a clinical-stage biopharmaceutical firm dedicated to discovering, developing, and bringing to market novel therapeutic proteins. Leveraging its proprietary DARPin® platform, the company is advancing a diverse pipeline of product candidates. Key among these is Abicipar, a DARPin-based treatment currently in Phase III clinical development for significant ophthalmic conditions like neovascular wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Additionally, their portfolio features multi-specific DARPin candidates targeting infectious diseases, such as MP0420 and MP0423, both designed to combat the SARS-CoV-2 virus (COVID-19). In the oncology space, Molecular Partners is advancing several programs: MP0310, in Phase Ia for immuno-oncology; MP0317, a Phase I tumor-localized immune agonist engineered to activate immune cells within tumors; and MP0274, also in Phase I, aimed at HER2-positive cancers. Further early-stage assets include MP0533, a CD3 T cell candidate for acute myeloid leukemia, and MP0250, which targets vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), and human serum albumin (HSA) to enhance therapeutic half-life. The company actively collaborates with leading pharmaceutical companies. Notable alliances include a partnership with Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; agreements with Amgen SA and Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc. They also maintain relationships with various other third-party collaborators. Established in 2004, Molecular Partners AG is headquartered in Schlieren, Switzerland.
Prezzo delle azioni
$3.98
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$152.44M
Variazione (1 giorno)
-1.29%
Variazione (1 anno)
14.68%
Paese
CH
Scambia Molecular Partners AG (MOLN)
Categoria
Healthcare
Capitalizzazione di mercato di Molecular Partners AG(MOLN)
Capitalizzazione di mercato: $152.44M
A partire dal October 2026, Molecular Partners AG ha una capitalizzazione di mercato pari a $152.44M. Questo rende Molecular Partners AG la 19481st azienda più preziosa al mondo per capitalizzazione di mercato secondo i nostri dati. La capitalizzazione di mercato è il valore totale delle azioni in circolazione di una società quotata e viene comunemente utilizzata per misurarne il valore.
Storia della capitalizzazione di mercato di Molecular Partners AG dal 2016 al 2026
MOLN in paragone con la classifica dei più popolari stocks
| Il prezzo per MOLN | Attivo B | Capitalizzazione del mercato a B | Risultati | |
|---|---|---|---|---|
$137,119
$153.94M
|
$5.252T | +3,411,889.37% | ||
|
$130,564
$153.94M
|
$5.001T | +3,248,788.52% | ||
|
$109,023
$153.94M
|
$4.176T | +2,712,778.82% | ||
|
$103,591
$153.94M
|
$3.968T | +2,577,600.77% | ||
|
$74,065.78
$153.94M
|
$2.837T | +1,842,915.48% |
